Portage Biotech Provides Update on Clinical-Stage and Development Programs Press ReleaseBy Gwen SchankerMarch 31, 2022...
Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting Press ReleaseBy Gwen SchankerMarch 9, 2022...
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year Press ReleaseBy Gwen SchankerFebruary 24, 2022...
Portage Biotech Announces New Appointments to its Management Team and Board of Directors Press ReleaseBy Gwen SchankerFebruary 15, 2022...
Portage Biotech Announces Participation in January 2022 Investor Conferences Press ReleaseBy Gwen SchankerJanuary 5, 2022...
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year Press ReleaseBy Portage Biotech, IncNovember 23, 2021...
Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference Press ReleaseBy Portage Biotech, IncNovember 22, 2021...
Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics’ INT230-6 (PORT-1) at November Scientific Conferences Press ReleaseBy Portage Biotech, IncNovember 15, 2021...
Portage Biotech Hosting Key Opinion Leader Webinar on How iNKT Agonists Could Improve Immuno-Oncology Treatment Press ReleaseBy Portage Biotech, IncNovember 10, 2021...
Portage Biotech Announces Participation in September 2021 Investor Conferences Press ReleaseBy Portage Biotech, IncSeptember 10, 2021...
